Talaris
Talaris Therapeutics is a late-clinical stage biotechnology company based in Louisville, KY, Boston, MA, and Houston, TX. Talaris is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as to induce durable remission in patients with severe autoimmune and immune-mediated disorders. The company was founded on technology discovered and developed by Dr. Suzanne Ildstad and operates its own cell processing facility in Louisville. Talaris is backed by leading life sciences investors Blackstone Life Sciences, Longitude Capital and Qiming Venture Partners USA.
Embracing a Healthy Lifestyle Post Kidney Transplant
Ch. 4: Phase 2 Data with FCR001, Designed to Induce Immune Tolerance in LDKT Recipients
Ch. 3: Protocol for Living Donor Kidney Transplant with FCR001, Designed to Induce Immune Tolerance
Ch. 6: FREEDOM-2 Phase 2 Trial with FCR001, Designed to Induce Immune Tolerance in LDKT Recipients
Ch. 5: FREEDOM-1 Phase 3 Trial With FCR001, Designed to Induce Immune Tolerance in LDKT Recipients
Ch. 2: FCR001: An Investigational Cell Therapy to Induce Immune Tolerance
Ch. 1: Outcomes and Treatment Burden Associated with Standard of Care for LDKT Recipients
Exploring the Potential Role of FCR001
Immunosuppression Challenges Post Transplant- Gisela Delgado, Patient Advocate
Clinical Trial Education and Awareness- Gisela Delgado, Patient Advocate
Burden of Immunosuppressive Medicines- Gisela Delgado, Patient Advocate
Talaris Therapeutics Presentation at The Transplantation Society (TTS) 2022 Congress
Innovative Paths to FREEDOM
Discovering a Path to FREEDOM
Gift of FREEDOM: A Donor's Perspective
FREEDOM to Follow a New Path
Talaris Therapeutics’ Presentation for the Alport Syndrome Foundation Webinar
FREEDOM-3 Information for Healthcare Professionals
Talaris Presentation at the 2022 Cutting Edge of Transplantation (CEoT) Transplant Summit
Talaris Presentation at the 2022 Systemic Sclerosis World Congress
Talaris Presentation at the 2022 Tandem Transplantation and Cellular Therapy Meeting
FREEDOM-3: A Quest for a Future Restored from Diffuse Scleroderma
FCR001, an investigational cell therapy: Harnessing the power of immune tolerance in LDKT for HCP
FREEDOM-1: A New Frontier in Living Donor Kidney Transplant